

WHAT IS CLAIMED IS:

- 1. A substantially pure or isolated polypeptide comprising a segment exhibiting sequence homology to a corresponding portion of a mature protein selected from the group consisting of:
 - i) TECK;
 - ii) MIP-3 α ;
 - iii) MIP-3 β ;
- 10 iv) DC CR; and


25

30

v) M/DC CR;

wherein said homology is at least about 70% identity and said portion is at least about 25 amino acids.

- 15 2. The protein of Claim 1, further comprising a second segment exhibiting:
 - a) at least about 90% identity over at least 9 amino acids; or
- b) at least about 80% identity over at least 17 amino acids.
 - 3. The polypeptide of Claim 1, wherein said polypeptide:
 - a) is from a warm blooded animal selected from the group of birds and mammals, including a mouse or human;
 - b) comprises a natural sequence from Tables 1 through 5;
 - c) exhibits a post-translational modification pattern distinct from a natural form of said polypeptide;
 - d) is made by expression of a recombinant nucleic acid;
 - e) comprises synthetic sequence;
 - f) is detectably labeled;
- 35 g) is conjugated to a solid substrate;
 - h) is conjugated to another chemical moiety;
 - i) is a fusion protein;



- j) is in a denatured conformation, including detergent denaturation;
- k) further comprises an epitope tag;
- 1) is an immunogenic polypeptide;
- m) has a defined homogeneous molecular weight;
 - n) is useful as a carbon source;
 - o) is an allelic variant of SEQ ID NO: 2, 4, 6, 8, 10, or 12;
- p) is a 3-fold or less substituted form of a natural sequence;
 - q) is in a sterile composition;
 - r) is in a buffered solution or suspension;
 - s) is in a regulated release device;
 - t) comprises a post-translational modification;
- u) is in a cell; or
 - v) is in a kit which further comprises instructions for use or disposal of reagents therein.
- 4. An isolated or recombinant nucleic acid encoding said protein of Claim 1, where said portion consists of sequence from the coding region of SEQ ID NO: 1, 3, 5, 7, 9, or 11.
- 5. The nucleic acid of Claim 4, wherein said nucleic acid:
 - a) exhibits at least about 80% identity to a natural cDNA encoding said segment;
 - b) is in an expression vector;
 - c) further comprises a promoter;
- d) further comprises an origin of replication;
 - e) is from a natural source;
 - f) is detectably labeled;
 - g) comprises synthetic nucleotide sequence;
 - h) is less than 6 kb;
- i) is from a mammal;
 - j) comprises a natural full length mature coding sequence;

15

20


25

35



k) is in a kit, which also comprises instructions for use or disposal of reagents therein;

- is a specific hybridization probe for a gene encoding said protein;
- m) is a PCR product; or
- n) is in a cell.
- 6. A method of using a purified nucleic acid of Claim 5, comprising a step of expressing said nucleic acid to produce a protein.
 - 7. An isolated or recombinant nucleic acid which encodes at least eight consecutive residues of SEQ ID NO: 2, 4, 6, 8, 10, or 12.
 - 8. The nucleic acid of Claim 7, which encodes at least:
 - a) twelve consecutive residues from SEQ ID NO: 2, and further comprises a coding sequence of at least 17 nucleotides from SEQ ID NO: 1;
 - b) twelve consecutive residues from SEQ ID NO: 4, and further comprises a coding sequence of at least 17 nucleotides from SEQ ID NO: 3;
 - c) twelve consecutive residues from SEQ ID NO: 6, and further comprises a coding sequence of at least 17 nucleotides from SEQ ID NO: 5;
 - d) twelve consecutive residues from SEQ ID NO: 8, and further comprises a coding sequence of at least 17 nucleotides from SEQ ID NO: 7;
- e) twelve consecutive residues from SEQ ID NO: 10, and further comprises a coding sequence of at least 17 nucleotides from SEQ ID NO: 9; or
 - f) twelve consecutive residues from SEQ ID NO: 12, and further comprises a coding sequence of at least 17 nucleotides from SEQ ID NO: 11.




- 9. The nucleic acid of Claim 7, wherein said nucleic acid:
 - a) exhibits at least about 80% identity to a natural cDNA encoding said segment;
 - b) is in an expression vector;
 - c) further comprises a promoter;
 - d) further comprises an origin of replication;
 - e) encodes a 3-fold or less substituted sequence from a natural sequence;
- 10 f) is from a natural source;
 - g) is detectably labeled;
 - h) comprises synthetic nucleotide sequence;
 - i) is less than 6 kb;
 - j) is from a mammal;
- 15 k) is attached to a solid substrate, including in a Southern or Northern blot;
 - 1) comprises a natural full length coding sequence;
 - m) is in a cel1; or
- n) is in a detection kit, which also comprises instructions for use or disposal of reagents therein.
- 10. A nucleic acid which hybridizes under stringent wash conditions of 55°C and less than 150 mM salt to the nucleic acid of Claim 7.
- 11. The nucleic acid of Claim 10, which exhibits at least about 85% identity over a stretch of at least about 30 nucleotides to a primate sequence of SEQ ID NO: 1, 3, 5, 30 7, 9, or 11.
 - 12. The nucleic acid of Claim 10, wherein:
 - a) said identity is at least 90%; or
 - b) said stretch is at least 75 nucleotides.

- 13. The nucleic acid of Claim 10, wherein:
 - a) said identity is at least 95%;\or

25

- b) said stretch is at least 100 nucleotides.
- 14. A binding compound comprising an antigen binding fragment from an antibody which binds to a protein of Claim5. 1.
 - 15. The binding compound of Claim 14, wherein:
 - a) said polypeptide is a mouse or human protein;
 - b) said antibody is raised against a mature peptide sequence of Tables 1 through 5;
 - c) said antibody is a monoclonal antibody;
 - d) said binding compound is attached to a solid substrate;
 - e) said binding compound is in a sterile composition;
- 15 f) said binding compound binds to a denatured antigen, including a detergent denatured antigen;
 - g) said binding compound is detectably labeled;
 - h) said binding compound is an Fv, Fab, or Fab2 fragment;
- i) said binding compound is conjugated to a chemical moiety;
 - j) said binding compound is in a detection kit which also comprises instructions for use or disposal of reagents therein.
 - 16. A cell which makes said antibody of Claim 14.
- 17. A method of purifying a polypeptide using a binding compound of Claim 14 to specifically separate said polypeptides from others.
 - 18. A method of generating an antigen-binding compound complex comprising the step of contacting a sample comprising said antigen to a sample comprising a binding compound of Claim 14.



25

- 19. A method of modulating physiology or development of a cell expressing a receptor for a chemokine selected from the group selected from:
 - a) TECK;
 - b) MIP-3 α ; or
 - c) MIP-3 β ;

comprising contacting said cell with a composition comprising:

- i) an agonist or mutein of said chemokine; or
- ii) an antibody antagonist of said chemokine.
 - 20. The method of Claim 19, wherein said cell is a macrophage or lymphocyte.
- 15 21. The method of Claim 19, wherein said physiology is selected from:
 - a) a cellular calcium flux;
 - b) a chemoattractant response;
 - c) cellular morphology modification responses;
- 20 d) phosphoinositide lipid turnover; or
 - e) an antiviral response.
 - 22. The method of Claim 19, wherein:
 - a) said receptor is DC CR and said chemokine is MIP- 3α ;
 - b) said physiology is pulmonary physiology; or
 - c) said cell is an eosinophil.